Metformin – the gold standard in type 2 diabetes: what does the evidence tell us?
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Metformin is a cornerstone of oral antidiabetic treatment. Recent joint American and European guidelines recommend instituting metformin therapy along with lifestyle modification at the time type 2 diabetes mellitus (T2DM) is diagnosed. Metformin acts to reduce hepatic gluconeogenesis and improve glucose uptake, and it may exert protective effects on pancreatic islet cells. Although metformin therapy produces substantial reductions in HbA1c, it does not produce body weight gain, is not associated with substantial risk for hypoglycaemia and has neutral to positive effects on lipids and blood pressure. The major adverse events associated with metformin are gastrointestinal. T2DM progresses even with initially effective monotherapy, and most patients will therefore receive combination therapy. When selecting agents to coadminister with metformin, a physician must consider efficacy in glycaemic control, safety, tolerability and any effects that may compromise overall efficacy (e.g. effects on body weight, lipids or blood pressure). In this regard, incretin‐based therapies have characteristics that make them particularly suitable for add‐on therapy with metformin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726
Cited by
mTOR- and HIF-1α–mediated aerobic glycolysis as metabolic basis for trained immunity
Cheng, S.-C., Quintin, J., Cramer, R. A., Shepardson, K. M., Saeed, S., Kumar, V., Giamarellos-Bourboulis, E. J., Martens, J. H. A., Rao, N. A., Aghajanirefah, A., et al. (2014) · Science · doi:10.1126/science.1250684 · Cited by 2,224
Metformin directly acts on mitochondria to alter cellular bioenergetics
Andrzejewski, S., Gravel, S.-P., Pollak, M., & St-Pierre, J. (2014) · Cancer & Metabolism · doi:10.1186/2049-3002-2-12 · Cited by 430
Zheng, Z., Chen, H., Li, J., Li, T., Zheng, B., Zheng, Y., Jin, H., He, Y., Gu, Q., & Xu, X. (2012) · Diabetes · doi:10.2337/db11-0416 · Cited by 282
Nazim, U. M., Moon, J.-H., Lee, J.-H., Lee, Y.-J., Seol, J.-W., Eo, S.-K., Lee, J.-H., & Park, S.-Y. (2016) · Oncotarget · doi:10.18632/oncotarget.8048 · Cited by 58
Fulghesu, A. M., Romualdi, D., Di Florio, C., Sanna, S., Tagliaferri, V., Gambineri, A., Tomassoni, F., Minerba, L., Pasquali, R., & Lanzone, A. (2012) · Human Reproduction · doi:10.1093/humrep/des262 · Cited by 48
“Since the incidence of these adverse effects could reach up to 30% in PCOS women (Palomba et al., 2009), and the magnitude is dose related, the minimal effective dosage should be preferred in order to reduce the patient’s symptoms (Bosi, 2009).”
Background
Metadata
- Authors
- Bosi, E.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2009-04-17
- Volume
- 11
- Issue
- s2
- Pages
- 3-8
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2019354525
- Cited by
- 134
- References
- 6
- FWCI
- 8.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metformin – the gold standard in type 2 diabetes: what does the evidence tell us? https://app.cochat.ai/papers/10.1111/j.1463-1326.2008.01031.x
- The paper
- Bosi, E. (2009). Metformin – the gold standard in type 2 diabetes: what does the evidence tell us? Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2008.01031.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.